Ideaya Biosciences enters additional supply pact with Gilead for IDE397
Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into an additional clinical ...
Amgen Reports Fourth Quarter And Full Year 2024 Financial Results
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
C&EN25d
Discovery of Novel Spirocyclic MAT2A Inhibitors Demonstrating High In Vivo Efficacy in MTAP-Null Xenograft Models
Medicinal Chemistry Department, Shanghai Haiyan Pharmaceutical Technology Co., Ltd., Pudong New Area, Shanghai 201203, China ...